Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 18, 2009

IDT Purchases VH Bio's Oligo Segment

  • Integrated DNA Technologies (IDT) acquired VH Bio’s oligonucleotide synthesis business. Since VH Bio is located in the U.K., and IDT is a Belgian company, the transaction will grow IDT’s customer base in the U.K.

    VH Bio will help IDT introduce its products to scientists in the U.K. Through the agreement, IDT will be able to offer a range of products with QC-checked sequences and next-day delivery.

    Joseph A. Walder, M.D., Ph.D., IDT’s founder and CEO, says that the deal is in line with the firm’s strategy to grow its product line and serve its customers. IDT has always understood the importance of quality, leading technology with the broadest scope, and truly collaborative customer service all at the lowest cost possible to the researcher, according to Dr. Walder.

    VH Bio retains a significant portfolio of products for immunologists and molecular biologists. These include HLA diagnostics, mAbs and lymphocyte separation products, as well as reagents and equipment.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »